Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome | Zendy

Norman Gaylis | Zendy; Angela Ritter | Zendy; Scott A. Kelly | Zendy; Nader Pourhassan | Zendy; Meenakshi Tiwary | Zendy; Jonah B. Sacha | Zendy; Scott G. Hansen | Zendy; Christopher Recknor | Zendy; Otto O. Yang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Author(s) -

Norman Gaylis,

Angela Ritter,

Scott A. Kelly,

Nader Pourhassan,

Meenakshi Tiwary,

Jonah B. Sacha,

Scott G. Hansen,

Christopher Recknor,

Otto O. Yang

Publication year - 2022

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciac226

Subject(s) - medicine , immunosuppression , covid-19 , immunology , clinical trial , immune system , antibody , placebo , chemokine receptor , chemokine , disease , infectious disease (medical specialty) , pathology , alternative medicine

In an exploratory trial treating “long COVID” with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research